In this article, GlobalData examines key reimbursement trends that reflect the current delays to patient access across the ...

YolTech has received FDA approval for its investigational new drug (IND) application for YOLT-101 to treat HeFH.

The EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.

Aytu BioPharma has signed an agreement with Fabre-Kramer Pharmaceuticals to commercialise Exxua in the US market for MDD.